Inhaled Antibiotics and Biologics for Lung Infections Caused by Pseudomonas | Research

The takeaway

Delivering antibiotics and biologic agents directly to the lungs can overcome Pseudomonas aeruginosa resistance mechanisms like biofilms and efflux pumps.

Direct lung delivery
Increases antibiotic concentration at the infection site while reducing systemic exposure

What the researchers found

Inhaled antibiotic and biologic formulations can achieve higher concentrations at the lung epithelial lining fluid, overcoming Pseudomonas resistance mechanisms including biofilm formation and efflux pumps.

Why it matters

Pseudomonas lung infections are a major cause of morbidity and mortality in chronic lung disease patients. Inhaled delivery could improve outcomes while reducing systemic side effects.

How the study worked

Narrative review of current research and development in inhaled antimicrobial formulations targeting Pseudomonas aeruginosa.

What this study cannot tell us

Review article — does not present new experimental data. Many inhaled biologic formulations remain in early development stages.

How to read the evidence

Narrative review summarizing existing research — no new primary data presented.

When this study was published

Published in 2026; covers the latest developments in inhaled antimicrobial formulations.

The bigger picture

This reflects a broader trend toward localized drug delivery and biologic therapies in infectious disease, moving beyond systemic antibiotics as resistance grows worldwide.

Questions still open

Which inhaled biologic formulations are closest to clinical approval for Pseudomonas infections?
Can inhaled antimicrobial peptides overcome biofilm resistance better than conventional antibiotics?

Common questions

Why are Pseudomonas lung infections so hard to treat?

Pseudomonas aeruginosa forms protective biofilms in the lungs and uses efflux pumps to expel antibiotics, making standard oral or IV treatments less effective.

What are biologic formulations for lung infections?

Biologics include antimicrobial peptides, monoclonal antibodies, and other protein-based therapies that can be formulated for inhalation to target lung infections directly.

Read the original research

Inhaled Antibiotic and Biologic Formulations Targeting Pseudomonas aeruginosa.

Pharmaceutics, 18(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Baral, Prodip Kumar; Dummer, Jack; Pletzer, Daniel; Das, Shyamal C. (2026). Inhaled Antibiotic and Biologic Formulations Targeting Pseudomonas aeruginosa.. Pharmaceutics, 18(2). https://doi.org/10.3390/pharmaceutics18020162